Collectively, these studies suggest that PD‐1/PD‐L1 and EGFR antibody combinations can enhance antitumor immunity, particularly in HNSCC and cSCC, but efficacy depends on tumor microenvironment (e.g., p16 status), treatment history, and inclusion of adjunct therapies like chemotherapy or radiotherapy. The gene discussed is EGFR; the disease is neoplasm.